JP2023135646A - 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン - Google Patents

血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン Download PDF

Info

Publication number
JP2023135646A
JP2023135646A JP2023039398A JP2023039398A JP2023135646A JP 2023135646 A JP2023135646 A JP 2023135646A JP 2023039398 A JP2023039398 A JP 2023039398A JP 2023039398 A JP2023039398 A JP 2023039398A JP 2023135646 A JP2023135646 A JP 2023135646A
Authority
JP
Japan
Prior art keywords
fusion protein
vegf receptor
weeks
receptor fusion
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023039398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023135646A5 (enExample
Inventor
ロバート・エル・ヴィッティ
L Vitti Robert
アリソン・ジェイ・バーライナー
J Berliner Alyson
カレン・チュー
Chu Karen
フリードリヒ・アスムス
Asmus Friedrich
セルジョ・カシミロ・ダ・シルバ・レアル
Casimiro Da Silva Leal Sergio
トーマス・アイシング
EIßING THOMAS
ケイ・ディー・リッテンハウス
D Rittenhouse Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Original Assignee
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3190733A external-priority patent/CA3190733A1/en
Application filed by Bayer Healthcare LLC, Regeneron Pharmaceuticals Inc filed Critical Bayer Healthcare LLC
Publication of JP2023135646A publication Critical patent/JP2023135646A/ja
Publication of JP2023135646A5 publication Critical patent/JP2023135646A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023039398A 2022-03-15 2023-03-14 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン Pending JP2023135646A (ja)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US202263319869P 2022-03-15 2022-03-15
US63/319,869 2022-03-15
US202263404512P 2022-09-07 2022-09-07
US63/404,512 2022-09-07
US202263404893P 2022-09-08 2022-09-08
US63/404,893 2022-09-08
US202263411594P 2022-09-29 2022-09-29
US63/411,594 2022-09-29
US202263412165P 2022-09-30 2022-09-30
US63/412,165 2022-09-30
US202263421298P 2022-11-01 2022-11-01
US63/421,298 2022-11-01
US202263434920P 2022-12-22 2022-12-22
US63/434,920 2022-12-22
US202363444480P 2023-02-09 2023-02-09
US63/444,480 2023-02-09
US202363447582P 2023-02-22 2023-02-22
US63/447,582 2023-02-22
CA3190733A CA3190733A1 (en) 2022-03-15 2023-02-22 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3,190,733 2023-02-22

Publications (2)

Publication Number Publication Date
JP2023135646A true JP2023135646A (ja) 2023-09-28
JP2023135646A5 JP2023135646A5 (enExample) 2026-03-24

Family

ID=85704021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023039398A Pending JP2023135646A (ja) 2022-03-15 2023-03-14 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン

Country Status (13)

Country Link
US (1) US20240024420A1 (enExample)
EP (1) EP4245312A1 (enExample)
JP (1) JP2023135646A (enExample)
KR (1) KR20230135013A (enExample)
CN (1) CN119136823A (enExample)
AU (2) AU2023233561A1 (enExample)
CA (1) CA3253640A1 (enExample)
CL (2) CL2024002733A1 (enExample)
IL (1) IL315374A (enExample)
JO (1) JOP20240202A1 (enExample)
MX (1) MX2024011079A (enExample)
TW (1) TW202400214A (enExample)
WO (1) WO2023177691A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2025217334A1 (en) * 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
KR20260096819A (ko) * 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
IL318292A (en) 2017-12-13 2025-03-01 Regeneron Pharma Devices and methods for administering precise doses
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
FI4185318T3 (fi) * 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon

Also Published As

Publication number Publication date
AU2023201638A1 (en) 2023-10-05
EP4245312A1 (en) 2023-09-20
TW202400214A (zh) 2024-01-01
IL315374A (en) 2024-11-01
JOP20240202A1 (ar) 2024-09-09
CL2025001818A1 (es) 2025-10-03
KR20230135013A (ko) 2023-09-22
US20240024420A1 (en) 2024-01-25
CL2024002733A1 (es) 2025-02-21
CN119136823A (zh) 2024-12-13
MX2024011079A (es) 2024-12-06
CA3253640A1 (en) 2023-09-21
WO2023177691A1 (en) 2023-09-21
AU2023233561A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
JP2023135645A (ja) 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン
AU2022275786B2 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
US20240024420A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20170080086A1 (en) Methods and formulations for treating vascular eye diseases
KR20220062279A (ko) 안질환의 치료 방법
EP4480491A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190733A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190726A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099475A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40094129A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40094129B (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313